Dyne Therapeutics, Inc. Net Income Loss

• Dyne Therapeutics, Inc. showed a decrease of -40.6% in Net Income Loss from 2024 to 2025.
• This data is from Dyne Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Dyne Therapeutics, Inc.'s Net Income Loss has declined by 2,903.0%.
• Historical annual values: Fiscal year 2025: -$446.21 million | Fiscal year 2024: -$317.42 million | Fiscal year 2023: -$235.94 million | Fiscal year 2022: -$168.10 million | Fiscal year 2021: -$149.29 million | Fiscal year 2020: -$59.44 million | Fiscal year 2019: -$14.86 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026